Trajenta (Linagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. By inhibiting DPP-4, Linagliptin prolongs the activity of incretin hormones, leading to increased insulin release and decreased glucagon levels. This mechanism helps regulate blood glucose levels. Clinical studies have shown that Trajenta effectively lowers hemoglobin A1c levels, improves glycemic control, and reduces the risk of hyperglycemia in adults with type 2 diabetes. It is typically prescribed as an adjunct to diet and exercise.